
The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study)
Keywords: Imatinib mesylate; Chemotherapy; CML; Myeloid blast crisis; Ph+ AML;